TGTX fundamentals
Key facts
Market capitalization6.31 BUSD
Basic EPS (TTM)0.16USD
Founded1993
CEOMichael Sean Weiss
Websitetgtherapeutics.com
About
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Valuation
Fundamental metrics to determine fair value of the stock
6.31 B
Price to earning ratio (P/E)
292.19xPrice to sales ratio (P/S)
19.87xMarket Cap
Net income
Revenue
Price to earning ratio (P/E)
292.19xPrice to sales ratio (P/S)
19.87xGrowth and Profitability
Company’s recent performance and margins
−34%
−17%
0%
17%
34%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−40.00 M
0.00
40.00 M
80.00 M
120.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
TGTX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company